Trial to Elucidate Tamoxifen and Raloxifene Role in Curbing Breast Cancer Incidence

Format: Info
Institute: National Cancer Institute (NCI)

Some women know they are at increased risk of developing break cancer, but scientists hope that certain drugs may curb that risk. To test two drugs for their efficacy, scientists launched a Study of Tamoxifen and Raloxifene (STAR) that is expected to yield results in 2006.

NCI, which is the main funder of the study or clinical trial, has produced a question-and-answer online fact sheet for people interested in learning more about STAR. The market name for tamoxifen is Nolvadex® and the name for raloxifene is Evista®.

Conducting the trial at more than 400 centers across the United States, Puerto Rico, and Canada, is the National Surgical Adjuvant Breast and Bowel Project. Enrollment closed in June 2004, after the trial reached its target of 19,000 post-menopausal women.

Next Steps
For more information, visit http://cis.nci.nih.gov/fact/4_19.htm.
For information in Spanish, visit http://cis.nci.nih.gov/fact/4_19s.htm.